Rhythm anticipates $385M-$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate
Source: SeekingAlpha
2026-02-26 15:09:36 ET
More on Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
- Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps - Slideshow
- Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster
- Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.07, revenue of $57.3M beats by $1.09M
- Rhythm Pharmaceuticals Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate
Rhythm Pharmaceuticals Inc.
NASDAQ: RYTM
RYTM Trading
1.35% G/L:
$91.80 Last:
241,693 Volume:
$90.73 Open:
RYTM Latest News
March 01, 2026 12:30:00 pm
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
February 26, 2026 07:00:00 am
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
RYTM Stock Data
$6,891,165,143
62,665,157
0.73%
95
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
